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BACKGROUND: The hypothesis that malignant tumours are generated by rare populations of cancer stem cells that are more
tumourigenic than other cancer cells has gained increasing credence. The objective of this study was to identify and characterise a
subpopulation of human sarcoma-initiating cells.
METHODS: We examined established rhabdomyosarcoma cell lines by flow cytometry. Tumourigenesis was examined by xenograft
models. Real-time PCR and immunohistochemistry were performed to examine the gene expression using cell lines and biopsy
specimens.
RESULTS: Rhabdomyosarcoma cell lines included small populations of fibroblast growth factor receptor 3 (FGFR3)-positive cells.
FGFR3-positive KYM-1 and RD cells were more strongly tumourigenic than FGFR3-negative cells. In addition, xenoengraftment of
33% of single FGFR3-positive KYM-1 cells yielded tumour formation. Stem cell properties of FGFR3-positive cells were further
established by real-time PCR, which demonstrated upregulation of undifferentiated cell markers and downregulation of differentiation
markers. We showed that in the absence of serum, addition of basic fibroblast growth factor maintained and enriched FGFR3-positive
cells. On the other hand, ciliary neurotrophic factor reduced the proportion of FGFR3-positive cells. Real-time PCR and
immunohistochemical examination revealed that embryonal rhabdomyosarcoma patient biopsy specimens were found to over-
express FGFR3.
CONCLUSIONS: Our findings suggest that rhabdomyosarcoma cell lines include a minor subpopulation of FGFR3-positive sarcoma-
initiating cells, which can be maintained indefinitely in culture and which is crucial for their malignancy.
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The hypothesis that malignant tumours are generated by rare
populations of tumour-initiating cells (TICs), also called cancer
stem cells, that are more tumourigenic than other cancer cells has
gained increasing credence (Clarke and Fuller, 2006). TICs were
initially identified in acute myeloid leukaemia (AML), and were
found capable of inducing AML in immunodeficient mice (Lapidot
et al, 1994; Bonnet and Dick, 1997). TICs have since been identified
in numerous other tumours, including melanoma, lung, head,
neck, pancreatic, prostate, colon, squamous cell cancers, and
benign tumours (Collins et al, 2005; Fang et al, 2005; Kim et al,
2005; Dalerba et al, 2007; Prince et al, 2007; Loebinger et al, 2008;
Xu et al, 2009). Although the AML TICs resemble and probably
originate from the transformation of a stem cell, it is possible that
other TICs originate from transformation of early or late
progenitor cells. Thus, the definition of a TIC is not related to
the cell of origin for a tumour but rather to its ability to self-renew,
initiate cancer, and give rise to more differentiated cells that have
lost the capacity for self-renewal and tumourigenic potential.
The notion that cancer is driven by TICs has obvious therapeutic
implications (Al-Hajj et al, 2004; Raguz and Yague, 2008).
The efficacy of tumour response to systemic therapy has
traditionally been assessed based on the bulk of tumour cells by
monitoring of changes in tumour size (Therasse et al, 2000).
However, if only a small fraction of TICs are capable of initiating
cancer, then curative therapy should be designed to target these
rare TICs rather than the bulk of nontumourigenic cells. Analysis
of TICs might thus yield novel therapeutic targets.
In this study, we attempted to identify rhabdomyosarcoma-
initiating cells (RICs) using cell surface markers. We examined
many markers of undifferentiated cells. We found that human
rhabdomyosarcoma cell lines include a small proportion of
fibroblast growth factor receptor 3 (FGFR3)-positive cells. Single
FGFR3-positive cells have the potential for tumour formation in
vivo. In addition, tumours formed by FGFR3-positive cells could
be used for serial propagation of tumours in animals. Moreover,
basic fibroblast growth factor (bFGF) could maintain and enrich
FGFR3-positive RICs in the KYM-1 cell line in the absence of
serum. The easy method of preparation we describe will be useful
for the development of anti-RICs target therapy.
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sMATERIALS AND METHODS
Cell culture
KYM-1 and RD rhabdomyosarcoma cell lines were purchased from
Health Sciences Research Resources Bank (Tokyo, Japan). The
A204 cell line was purchased from ATCC (Manassas, VA, USA).
These cells were cultured in DMEM, supplemented with 10% FCS,
100 units per ml penicillin G, and 100mgml
 1 streptomycin
(Invitrogen, Carlsbad, CA, USA). In some experiments, KYM-1
cells were cultured in serum-free S-Clone (Sanko Junyaku, Japan)
containing 10ngml
 1 bFGF, 10ngml
 1 epidermal growth factor
(EGF), 2.5ngml
 1 transforming growth factor beta (TGF-b),
10ngml
 1 ciliary neurotrophic factor (CNTF), 10ngml
 1 plate-
let-derived growth factor (PDGF)-AA, 10ngml
 1 PDGF-BB, and
5mgml
 1 heparin. Normal human skeletal muscle cells (HSkMC)
were purchased from TOYOBO (Osaka, Japan). HSkMC were
cultured in skeletal muscle cell growth medium (Cell Applications
Inc., San Diego, CA, USA) or DMEM, supplemented with 10% FCS,
100units per ml penicillin G, and 100mgml
 1 streptomycin
(Invitrogen). In all experiments, cells were maintained in
100mm culture dishes (Nunc, New York, NY, USA) at 371Ci na
humidified 5% CO2 per 95% air atmosphere.
Flow cytometry analysis and sorting
Fluorescence-activated cell sorting analysis was performed using
an Epics Altrta (Beckman Coulter, Fullerton, CA, USA). Cells were
conjugated with anti-FGFR3 antibody (R&D, Minneapolis, MN,
USA) for 30min on ice. Cells were washed three times in PBS, re-
suspended in the same buffer at 5 10
6 per ml, and kept on ice
until analysis. Live single cells (fixed FSC-A/FSC-W ratio; PI
negative) were gated for analysis.
Rhabdomyosarcoma patients’ biopsy specimens
We obtained two biopsy specimens of human rhabdomyosarcoma
from primary lesions. Pathological examination revealed that
patient 1 had embryonal rhabdomyosarcoma and patient 2 had
alveolar rhabdomyosarcoma. Biopsy was performed before chemo-
therapy or radiotherapy to make the diagnosis. Control muscle was
obtained from surgery for scoliosis. The study protocol was
approved by the institutional review board of the Kagoshima
University. All patients and controls gave written informed consent.
Real-time PCR
Each sample was run minimally at three concentrations in
triplicate. All primer sets amplified 100–200bp fragments. Primers
were designed by Primer3. Total RNA was extracted using the
miR-Vana RNA isolation system (Ambion, Austin, TX, USA) or
TRIzol (Invitrogen). Reactions were run using SYBR Green (Bio-
Rad, Hercules, CA USA) on a MiniOpticon machine (Bio-Rad).
The comparative Ct (DDCt) method was used to determine fold
change in expression using bII-macroglobulin, ACTB,o rGAPDH.
The following primers were used: CD34: 5- CACCCTGTGTCTCA
ACATGG-3, 5-GGCTTCAAGGTTGTCTCTGG-3; PAX3: 5- GCCT
GACGTGGAGAAGAAAA-3, 5-GCCTCCTCCTCTTCACCTTT-3; PAX7:
5-GAACCTGACCTCCCACTGAA-3, 5-CCTCTGTCAGCTTGGTCCTC-3;
MYF5: 5-AATTTGGGGACGAGTTTGTG-3, 5- CATGGTGGTGGACTT
CCTCT-3; NANOG: 5-AATACCTCAGCCTCCAGCAGATG-3, 5-TGCGT
CACACCATTGCTATTCTTC-3; OCT-4: 5-GAGAACCGAGTGAGAGG
CAACC-3, 5-CATAGTCGCTGCTTGATCGCTTG-3, SOX2: 5-AGAAC
CCCAAGATGCACAAC-3, 5-CGGGGCCGGTATTTATAATC-3; MYH1:
5-GCTCATCGAGAAGCCTATGG-3, 5-CAAAGAGAAGTGGGCCTCAG
-3; desmin: 5-CATCGCGGCTAAGAACATTT-3, 5-GCCTCATCAGGG
AATCGTTA-3; myogenin: 5-TGGGCGTGTAAGGTGTGTAA-3, 5-CGA
TGTACTGGATGGCACTG-3; dystrophin: 5-ACCACCTCTGACCCTAC
ACG-3, 5-GCAATGTGTCCTCAGCAGAA-3; b2-microglobulin:5 - T C A A
TGTCGGATGGATGAAA-3, 5-GTGCTCGCGCTACTCTCTCT-3; ACTB:
5-AGAAAATCTGGCACCACACC-3, 5-AGAGGCGTACAGGGATAGCA-3;
GAPDH: 5-GAAGGTGAAGGTCGGAGTC-3, 5-GAAGATGGTGAT
GGGATTTC-3.
Immunohistochemical examination
We obtained two biopsy specimens of human rhabdomyosarcoma
from primary lesions. Pathological examination revealed that
patient 1 had embryonal rhabdomyosarcoma and patient 2 had
alveolar rhabdomyosarcoma. Anti-FGFR3 (diluted 1:200, R&D)
was used as a primary antibody. Rhodamine-conjugated donkey
anti-rabbit IgG antibody (diluted 1:200; Chemicon, Billerica, MA,
USA) was used as a secondary antibody. The cells were counter-
stained with Hoechst 33258 to identify nuclei. Immunohistochem-
istry with second antibody alone without primary antibody was
performed as a control.
Animal experiments
KSN/SLC nude mice were purchased from SLC. FGFR3-positive
cells were collected by magnetic sorting by MACS according to the
manufacturer’s recommendations (Miltenyi Biotec, Gladbach,
Germany). The following antibodies were used: PE-conjugated
anti-FGFR3 antibody (R&D) and anti-PE Microbeads (Miltenyi
Biotec). Cell inoculation was performed as reported earlier
(Tanaka et al, 2009). Cells were mixed with a collagen gel, and
were inoculated subcutaneously in 5-week-old nude mice. Grafts
were excised and small portions of tumour (20mg) were serially
inoculated into other nude mice. In addition, graft was excised and
trypsinised. Each number of cells was serially inoculated into other
mice. Grafts were fixed with 10% buffered formaldehyde and
stained with hematoxylin and eosin. All experimental procedures
were performed in compliance with the guiding principles for the
Care and Use of Animals described in the American Journal of
Physiology and with the Guidelines established by the Institute of
Laboratory Animal Sciences, Faculty of Medicine, Kagoshima
University. All efforts were made to minimise animal suffering, to
reduce the number of animals used, and to use possible
alternatives to in vivo techniques.
RESULTS
Rhabdomyosarcoma cell lines include a small portion of
FGFR3-positive cells
To determine whether any of the established osteosarcoma and
rhabdomyosarcoma cell lines included small portions of undiffer-
entiated cell marker-positive cells, we performed flow cytometry.
We examined many markers of undifferentiated cell, such as side
population (SP), CD9, CD10, CD13, CD29, CD31, CD34, CD44,
CD117, CD133, FLT3, LNGFR, and FGFR3 (Caligaris-Cappio et al,
1985; Robinson et al, 1999; Erices et al, 2000; Singh et al, 2003;
Kondo et al, 2004; Bobis et al, 2006; Jones et al, 2006; Small, 2008).
We found that three rhabdomyosarcoma cell lines, KYM-1, RD,
and A204, each included a small proportion of FGFR3-positive
cells (1.6–2.6%) (Figure 1).
The malignancy of KYM-1 and RD cells in vivo depends to
a large extent on FGFR3-positive RICs
To determine whether the subset defined by FGFR3 was enriched
for RICs, we compared the abilities of FGFR3þ and FGFR3 
rhabdomyosarcoma cells to initiate tumour formation in vivo.
After 8W, all mice inoculated with 100 KYM-1 cells had formed
tumours. After 5W, in 5 out of 6 of 10 FGFRþ KYM-1 cells
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sinoculated mice, there was tumour formation. In contrast, in 1 out
of 6 of 10 FGFR  KYM-1 cells inoculated mice, there was tumour
formation. Surprisingly, 2 out of 6 of only single FGFR3þ KYM-1
cell inoculated mice also exhibited tumour formation. (Figure 2A).
Next, we examined RD cells. After 6W, in 2 out of 3 of 100 FGFRþ
RD cells inoculated mice, there was tumour formation. In contrast,
in 0 out of 3 of 100 FGFR  RD cells inoculated mice, there was
tumour formation after 12W inoculation. In addition, in 1 out of 3
of 10 FGFRþ RD cells inoculated mice, there was tumour
formation. In contrast, in 0 out of 3 of 10 FGFR  RD cells
inoculated mice, there was tumour formation (Figure 2C). We next
performed serial transplantation. Small portions of formed tumour
(20mg) were excised and then inoculated into other nude mice. Six
of six tumours formed by FGFR3þ cells inoculated into mice
formed tumour. In contrast, none of six tumours were formed by
FGFR  KYM-1 cells. In addition, 3 out of 3 of 1000 cells prepared
from FGFR3þ tumour inoculated mice formed tumour
(Figure 2D). In contrast, 0 out of 3 of 1000 cells prepared from
FGFR  tumour formed tumour (Figure 2D). Immunohistochemi-
cal examination revealed that tumours formed by FGFR3þ KYM-1
cell contained both FGFR3þ cells and FGFR3  cells in vivo
(Figure 2E).
RICs express undifferentiated cell markers
We next examined the expression of genes specific to skeletal
muscle development or embryonic stem cells. RNA from FGFR3þ
KYM-1 or FGFR3  KYM-1 cells was analysed by real-time PCR for
CD34, PAX3, PAX7, MYF5, NANOG, OCT4, SOX2, myosin heavy
chain 1 (MYH1), desmin, myogenin, and dystrophin. Real-time
PCR revealed that expression of CD34 and PAX3 in FGFR3þ cells
was markedly increased by 7.23- and 2.47-fold, respectively. In
addition, the expression of PAX7, MYF5, NANOG, OCT3, and SOX2
was slightly increased by 1.15-, 1.13-, 1.35-, 1.56-, and 1.5-fold,
respectively. On the other hand, the expression of the differ-
entiated muscle markers MYH1, desmin, myogenin, and dystrophin
was decreased to 0.85-, 0.91-, 0.81-, and 0.25-fold baseline levels,
respectively (Figure 3).
RICs can be maintained and enriched by bFGF
We then examined which factor(s) can maintain KYM-1 FGFR3þ
cells in serum-free culture media. We tested bFGF, EGF, TGF-b1,
CNTF, PDGF-AA, and PDGF-BB as candidates. These mitogens are
important factors in maintaining many types of progenitor cells
(Marmur et al, 1998; Kondo et al, 2004; Vallier and Pedersen,
2005). We first cultured unfractionated KYM-1 cells in serum-free
culture medium alone or with a mixture of bFGF, EGF, TGF-b,
CNTF, PDGF-AA, and PDGF-BB. KYM-1 cells could not grow
without growth factors. On the other hand, this growth factor
cocktail promoted KYM-1 cell growth. We next examined which
mitogen is essential for KYM-1 cell growth, by withdrawing each
mitogen individually. All culture conditions promoted KYM-1
growth but bFGF withdrawal (Figure 4A). These findings suggested
that bFGF is essential for KYM-1 survival and proliferation. We
cultured 1000 KYM-1 cells in each condition and counted 20 days
after culture. Addition of EGF to serum-free culture medium with
bFGF appreciably stimulated KYM-1 cell growth approximately
three-fold, the same as neural progenitor cells (Figure 4B)
(Kitchens et al, 1994). On the other hand, when cultured in
serum-free culture medium with EGF alone, KYM-1 cells could not
survive. We then stained cells with anti-FGFR3 antibody and
analysed them by flow cytometry. When cultured in serum-free
medium with bFGF, FGFR3þ cells were maintained, and their
proportion increased to 7.6–9.2%. In addition, when cultured in
both bFGF and EGF, FGFR3þ cells increased to 4.2–6.0 % and
total cell number increased three-fold (Figure 4C). We next
examined which factor prevents expansion of FGFR3þ cells.
When KYM-1 cells were cultured with bFGF plus CNTF, CNTF
reduced the proportion of FGFR3þ cells by approximately 15%
(Figure 4D), although CNTF did not affect the total number of
KYM-1 cells. These findings suggest that RICs can be maintained
and increased in bFGF alone and that a combination of bFGF and
EGF can increase cell numbers. On the other hand, CNTF
decreased the proportion of RICs.
FGFR3 was upregulated in rhabdomyosarcomapatient
biopsy specimens
We next examined the expression of FGFR3 in patient biopsy
specimens. Real-time PCR revealed that FGFR3 was upregulated
in embyonal rhabdomyosarcoma patient biopsy specimens
(Figure 5A). Immunohistochemical examination revealed that a
portion of rhabdomyosarcoma cells expressed FGFR3. The
intensity of FGFR3 expression differed among rhabdomyosarcoma
cells (Figure 5B).
DISCUSSION
Although there is an expanding literature supporting the existence
of cancer stem cells, important caveats of these studies continue
to provoke debate. The current definitive test for a cancer stem
cell is the capacity to propagate tumours as xenografts in
immunocompromised mice (Clarke et al, 2006). We have
described here the isolation of a highly tumourigenic subpopula-
tion of cells from human rhabdomyosarcoma cell lines in accord
with terminology. To our knowledge, this is the first isolation of
Percentage of FGFR3+ cells
KYM-1 RD
2.1%
0% 2.6%
0%
Control mAB FGFR3+ Control mAB
A204
0% 1.6%
Control mAB FGFR3+
FGFR3+
100
100 100
100 1 1 100 100
Figure 1 Rhabdomyosarcoma cell lines include a small portion of
FGFR3-positive cells. Cells of human KYM-1 rhabdomyosarcoma (A),
human RD rhabdomyosarcoma (B), and human A204 rhabdomyosarcoma
(C) cell lines were labelled with anti-FGFR3 antibody and then analysed by
flow cytometry. These three human rhabdomyosarcoma cell lines included
small subpopulations of FGFR3-positive cells. These experiments were
repeated at least three times with similar results.
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smalignant progenitors from human rhabdomyosarcoma to be
described.
Initially, to identify candidate RICs, we used a side popula-
tion method as reported earlier (Kondo et al, 2004; Setoguchi
et al, 2004). We detected approximately 1–3% SP cells among
KYM-1 cells. We sorted SP and non-SP cells and then inoculated
them into nude mice subcutaneously, but could not detect
differences between them in tumourigenisity (data not shown).
We next examined CD133, which has been reported to be a
cancer stem cell marker (Singh et al, 2003; Hermann et al, 2007;
Ricci-Vitiani et al, 2007; Chearwae and Bright, 2008; Mizrak et al,
2008). KYM-1 cells also included a small proportion of CD133-
positive cells. We sorted CD133þ and CD133  cells and then
inoculated them into nude mice subcutaneously, but found no
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Figure 2 The malignancy of rhabdomyosarcoma cells in vivo depends to a large extent on the FGFR3-positive cells. FGFR3-dependent cell sorting was
performed using immunomagnetic selection, with culture for one night to exclude dead cells by mechanical stress followed by inoculation of cells from either
population interdermally into nude mice. (A) Primary tumour formation by KYM-1, FGFR3 , or FGFR3þ cells. After 8W, all mice inoculated with 100
KYM-1 cells had formed tumours. After 5W, in 5 out of 6 of 10 FGFRþ KYM-1 cells inoculated mice, there was tumour formation. In contrast, in 1 out of 6
of 10 FGFR  KYM-1 cells inoculated mice, there was tumour formation after 12W inoculation. Surprisingly, 2 out of 6 of only single FGFR3þ KYM-1 cell
inoculated mice also exhibited tumour formation. In contrast, 0 out of 6 of single KYM-1 FGFR cell inoculated mice formed tumour after 12W inoculation.
(B). Ten FGFR3-positive cells form tumour 8 weeks after inoculation. (C). Primary tumour formation by RD, FGFR3 , or FGFR3þ cells. After 6W, in 2 out
of 3 of 100 FGFRþ RD cells inoculated mice, there was tumour formation. In contrast, in 0 out of 3 of 100 FGFR  RD cells inoculated mice, there was
tumour formation after 12W inoculation. In addition, in 1out of 3 of 10 FGFRþ RD cells inoculated mice, there was tumour formation. In contrast, in 0 out
of 3 of 10 FGFR  RD cells inoculated mice, there was tumour formation after 12W inoculation. (D) Secondary tumour formation by FGFR3  or FGFR3þ
KYM-1 cells. We next performed serial transplantation. Small portions of formed tumour (20mg) were excised and then inoculated into other nude mice.
Six of six tumours formed by FGFR3þ KYM-1 cells inoculated into mice formed tumour. In contrast, none of six tumours formed by FGFR  KYM-1 cells
inoculated into mice formed tumour after 12W inoculation. In addition, 3 out of 3 of 1000 cells prepared from FGFR3þ tumour inoculated mice formed
tumour. In contrast, 0 out of 3 of 1000 cells prepared from FGFR  tumour inoculated mice formed tumour after 12W inoculation. (E) HE staining of
tumour formed by FGFR3þ KYM-1cells. Immunohistochemical examination revealed that tumour formed by FGFR3þ KYM-1cells contains both FGFR3þ
and FGFR3  cells (red: FGFR3, blue: Hoechst). * FGFR3  vs FGFR3þ Po0.05, * * FGFR3  vs FGFR3þ Po0.01.
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sdifferences between them in tumourigenisity (data not shown).
In addition, we were unable to identify subpopulations by other
undifferentiated cell markers. In our study, RICs were enriched
in rhabdomyosarcoma subpopulations defined by FGFR3 alone.
These findings suggest that sarcomas may differ from other
epithelial malignancies, including cancers of the breast, head and
neck, lung, pancreas, colon, and prostate (Al-Hajj et al, 2003;
Collins et al, 2005; Fang et al, 2005; Kim et al, 2005; Dalerba et al,
2007; Li et al, 2007; Prince et al, 2007). It has been reported that
FGFR3 is expressed in human muscle from 11 weeks of gesta-
tion and is decreased in adult muscle (Sogos et al, 1998). Muscle
stem cells (muscle satellite cells) express FGFR3 whereas muscle-
derived fibroblasts do not (Sheehan and Allen, 1999). These
findings suggest that FGFR3 is expressed not only in RICs but also
in muscle stem cells. In addition to exhibiting aggressive
tumourigenisity, RICs expressed stem cell markers intensely with
fewer markers of differentiation. These findings suggest that RICs
have the characteristics of undifferentiated cells. In particular,
RICs upregulated CD34 and that downregulated dystrophin. These
genes are muscle cell linage specific. These findings suggest that
RICs are already to some extent committed to the muscle cell
linage from more undifferentiated stages such as mesenchymal
stem cells.
Rhabdomyosarcoma is composed of embryonal and alveolar
subtypes. KYM-1 and RD is established from embryonal rhabdo-
myosarcoma (McAllister et al, 1969; Sekiguchi et al, 1985).
The subtype of A204 was not described in article of cell line
establishment (Giard et al, 1973). Embryonal rhabdomyosarcoma
contain primitive undifferentiated round cells (Gallego Melcon and
Sanchez de Toledo Codina, 2007). Consistent with these findings,
we showed that embryonal rhabdomyosarcoma cell lines contain
undifferentiated RICs. In addition, real-time PCR revealed that the
amount of FGFR mRNA in the embryonal rhabdomyosarcoma
biopsy sample was more than that in the normal skeletal muscle or
alveolar rhabdomyosarcoma sample.
Mammals have four FGFR tyrosine kinase genes (FGFR1–4)
(Eswarakumar et al, 2005). FGFRs are composed of an extracellular
ligand-binding domain, a transmembrane domain, and a split
cytoplasmic tyrosine kinase domain. In this study, we examined
only FGFR3. Whether related members of the FGFR family are
markers of RICs requires further study. We found that bFGF could
maintain and expand RICs. It has been reported that bFGF
promotes proliferation and inhibits differentiation of muscle
satellite cells (Guthridge et al, 1992; Lefaucheur and Sebille,
1995). The bFGF binds to FGFR1, FGFR2, FGFR3, and FGFR4.
The binding of bFGF to FGFR3 activate FGF signalling path-
way (Ornitz and Leder, 1992; Maric et al, 2007). These data sug-
gest that FGFR3 is not only a cell surface marker for RICs but
also mediates signals important for RICs maintenance and
proliferation. In addition, we found that CNTF reduced the
proportion of RICs. There is increasing evidence that chemother-
apy and radiation can each efficiently eradicate the majority of
malignant cells within neoplastic lesions. However, these regimens
frequently fail to eliminate a minor subpopulation of resistant
cancer stem cells (Trumpp and Wiestler, 2008). Inhibition of
FGFR3 signalling or activation of CNTF signalling might thus be a
good candidate for anti-cancer stem cell therapy for rhabdomyo-
sarcoma.
Recent studies have suggested that FGFR3 has a significant
function in the pathogenesis and progression of some malignan-
cies including thyroid carcinoma, bladder carcinoma, multiple
myeloma, and peripheral T-cell lymphoma (Cappellen et al, 1999;
Onose et al, 1999; Kastrinakis et al, 2000; Yagasaki et al, 2001;
Wolff et al, 2005). Whether FGFR3 is a marker of TICs in these
malignancies requires further study.
In our study, 33% of single KYM-1 RICs formed tumours. This
TIC frequency is somewhat higher than previously reported for
other TICs (Singh et al, 2003; Hermann et al, 2007; Ricci-Vitiani
et al, 2007; Mizrak et al, 2008). These more strong tumourigenic
RICs may be more useful than other TICs for examining the
molecular mechanisms of tumour initiation, proliferation, anti-
apoptotic capacity, and metastasis. Although RICs are enriched in
the rhabdomyosarcoma subpopulations defined by FGFR3, not
every FGFR3þ cell is an RIC, as 67% of purified single RICs did
not form tumours. Quintana et al reported that frequency of
tumourigenisity in mice depends to a large extent on the status of
immunodeficiency (Quintana et al, 2008). When melanoma cells
were transplanted into NOD/SCID mice, 1 in 111000 cells formed
tumour. When transplanted into highly immunocompromised
NOD/SCID interleukin-2 receptor g chain null mice, 27% of single
cells formed tumours. The tumourigenisity of RICs might vary
depending on the experimental conditions used, such as the tissue
site of xenotransplantation, or differences among recipient
immunodeficient mice.
In summary, we identified FGFR3-positive RICs in human
rhabdomyosarcoma cell lines. RICs were more strongly tumouri-
genic than other previously reported TICs. Our easy method of
preparing RICs may prove useful for further exploration of
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Figure 3 FGFR3-positive cells over-expressed undifferentiated cell genes. (A) As demonstrated by real-time PCR, FGFR3þ cells (RICs) over-express
several undifferentiated cell marker genes compared with FGFR3  cells (B). Real-time PCR revealed that FGFR3þ cells (RICs) exhibited downregulation of
several differentiated cell marker genes compared with FGFR3  cells. The comparative Ct (DDCt) method was used to determine fold change in expression
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Figure 4 Increase in proportion of KYM-1 FGFR3-positive cells with bFGF. (A) KYM-1 cells were cultured in serum-free medium with or without growth
factor cocktails. Cells were cultured for 3 weeks and then photographed. When cultured without bFGF, KYM-1 cells did not increase in proportion. (B)
1000 KYM-1 cells were cultured for 3 weeks in serum-free medium with bFGF, EGF, or both or neither and were then photographed. When cultured with
bFGF, KYM-1 cells were maintained. Cell number was increased with bFGF plus EGF. (C) Proportion of FGFR3þ cells was analysed by flow cytometry.
KYM-1 cells were cultured in FCS, bFGF, or bFGF plus EGF for 3 weeks. The proportion of FGFR3-positive RICs was increased by bFGF. When cultured with
bFGF plus EGF, total number of cells was increased three-fold compared with bFGF alone. All experiments were repeated at least three times with similar
results. (D) Proportion of FGFR3þ cells was analysed by flow cytometry. KYM-1 cells were cultured in FCS, bFGF, or bFGF plus CNTF for 3 weeks. When
cultured with bFGF plus CNTF, the proportion of FGFR3þ cells was markedly decreased compared with bFGF alone or FCS. All experiments were
repeated at least three times with similar results.
Tumour formation by single FGFR3-positive RICs
M Hirotsu et al
2035
British Journal of Cancer (2009) 101(12), 2030–2037 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
spathogenesis of rhabdomyosarcoma and molecular characterisa-
tion of cancer stem cells.
ACKNOWLEDGEMENTS
This work was supported by Grants-in-Aid for Scientific
Research (B) 18390419, (C) 19591725, (C) 21591919 (KAKENHI),
and Grant-in-Aid from the Ministry of Health, Labour and
Welfare for the Third Term Comprehensive Control Research for
Cancer.
Conflict of interest
The authors declare no conflict of interest.
REFERENCES
Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF (2004)
Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:
43–47
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003)
Prospective identification of tumorigenic breast cancer cells. Proc Natl
Acad Sci USA 100: 3983–3988
Bobis S, Jarocha D, Majka M (2006) Mesenchymal stem cells: characteristics
and clinical applications. Folia Histochem Cytobiol 44: 215–230
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:
730–737
Caligaris-Cappio F, Bergui L, Tesio L, Pizzolo G, Malavasi F, Chilosi M,
Campana D, van Camp B, Janossy G (1985) Identification of malignant
plasma cell precursors in the bone marrow of multiple myeloma. J Clin
Invest 76: 1243–1251
Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau
X, Chopin D, Thiery JP, Radvanyi F (1999) Frequent activating mutations
of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18–20
Chearwae W, Bright JJ (2008) PPARgamma agonists inhibit growth
and expansion of CD133+ brain tumour stem cells. Br J Cancer 99:
2044–2053
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J,
Weissman IL, Wahl GM (2006) Cancer stem cells – perspectives on
current status and future directions: AACR Workshop on cancer stem
cells. Cancer Res 66: 9339–9344
Clarke MF, Fuller M (2006) Stem cells and cancer: two faces of eve. Cell 124:
1111–1115
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective
identification of tumorigenic prostate cancer stem cells. Cancer Res 65:
10946–10951
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A,
Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF
(2007) Phenotypic characterization of human colorectal cancer stem
cells. Proc Natl Acad Sci USA 104: 10158–10163
Erices A, Conget P, Minguell JJ (2000) Mesenchymal progenitor cells in
human umbilical cord blood. Br J Haematol 109: 235–242
Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling
by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:
139–149
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA,
Xu X, Elder DE, Herlyn M (2005) A tumorigenic subpopulation with stem
cell properties in melanomas. Cancer Res 65: 9328–9337
FGFR3 Nuclei Merge
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
m
R
N
A
30
25
20
15
10
5
0
Normal
Patient 1
Patient 2
26.2
1 1.5
FGFR3
Figure 5 FGFR3 is over-expressed in rhabdomyosarcoma patient specimens. (A) We obtained two biopsy specimens of human rhabdomyosarcoma
from primary lesions. Pathological examination revealed that patient 1 had embryonal rhabdomyosarcoma and patient 2 had alveolar rhabdomyosarcoma.
Real-time PCR revealed that the amount of FGFR mRNA in the embryonal rhabdomyosarcoma biopsy sample was more than that in the normal skeletal
muscle or alveolar rhabdomyosarcoma sample. (B) Immunohistochemistry revealed that FGFR3 was expressed in a portion of rhabdomyosarcoma patient 1
biopsy specimens. Arrows indicate FGFR3-negative cells. Immunohistochemical examination showed that 11.2±2.8% cells were positive for FGFR3.
Tumour formation by single FGFR3-positive RICs
M Hirotsu et al
2036
British Journal of Cancer (2009) 101(12), 2030–2037 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sGallego Melcon S, Sanchez de Toledo Codina J (2007) Molecular biology of
rhabdomyosarcoma. Clin Transl Oncol 9: 415–419
Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks
WP (1973) In vitro cultivation of human tumors: establishment of
cell lines derived from a series of solid tumors. J Natl Cancer Inst 51:
1417–1423
Guthridge M, Wilson M, Cowling J, Bertolini J, Hearn MT (1992) The role
of basic fibroblast growth factor in skeletal muscle regeneration. Growth
Factors 6: 53–63
Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns
CJ, Heeschen C (2007) Distinct populations of cancer stem cells
determine tumor growth and metastatic activity in human pancreatic
cancer. Cell Stem Cell 1: 313–323
Jones EA, English A, Kinsey SE, Straszynski L, Emery P, Ponchel F,
McGonagle D (2006) Optimization of a flow cytometry-based protocol
for detection and phenotypic characterization of multipotent mesench-
ymal stromal cells from human bone marrow. Cytometry B Clin Cytom
70: 391–399
Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C
(2000) Molecular aspects of multiple myeloma. Ann Oncol 11: 1217–1228
Kim CFB, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S,
Crowley D, Bronson RT, Jacks T (2005) Identification of bronchioalveo-
lar stem cells in normal lung and lung cancer. Cell 121: 823–835
Kitchens DL, Snyder EY, Gottlieb DI (1994) FGF and EGF are mitogens for
immortalized neural progenitors. J Neurobiol 25: 797–807
Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation
of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci
USA 101: 781–786
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J,
Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating
human acute myeloid leukaemia after transplantation into SCID mice.
Nature 367: 645–648
Lefaucheur JP, Sebille A (1995) Basic fibroblast growth factor promotes in
vivo muscle regeneration in murine muscular dystrophy. Neurosci Lett
202: 121–124
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke
MF, Simeone DM (2007) Identification of pancreatic cancer stem cells.
Cancer Res 67: 1030–1037
Loebinger MR, Giangreco A, Groot KR, Prichard L, Allen K, Simpson C,
Bazley L, Navani N, Tibrewal S, Davies D, Janes SM (2008) Squamous cell
cancers contain a side population of stem-like cells that are made
chemosensitive by ABC transporter blockade. Br J Cancer 98: 380–387
Maric D, Fiorio Pla A, Chang YH, Barker JL (2007) Self-renewing and
differentiating properties of cortical neural stem cells are selectively
regulated by basic fibroblast growth factor (FGF) signaling via specific
FGF receptors. J Neurosci 27: 1836–1852
Marmur R, Kessler JA, Zhu G, Gokhan S, Mehler MF (1998) Differentiation
of oligodendroglial progenitors derived from cortical multipotent cells
requires extrinsic signals including activation of gp130/LIFbeta recep-
tors. J Neurosci 18: 9800–9811
McAllister RM, Melnyk J, Finkelstein JZ, Adams Jr EC, Gardner MB (1969)
Cultivation in vitro of cells derived from a human rhabdomyosarcoma.
Cancer 24: 520–526
Mizrak D, Brittan M, Alison MR (2008) CD133: molecule of the moment.
J Pathol 214: 3–9
Onose H, Emoto N, Sugihara H, Shimizu K, Wakabayashi I (1999)
Overexpression of fibroblast growth factor receptor 3 in a human thyroid
carcinoma cell line results in overgrowth of the confluent cultures. Eur J
Endocrinol 140: 169–173
Ornitz DM, Leder P (1992) Ligand specificity and heparin dependence
of fibroblast growth factor receptors 1 and 3. J Biol Chem 267:
16305–16311
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P,
Weissman IL, Clarke MF, Ailles LE (2007) Identification of a
subpopulation of cells with cancer stem cell properties in head
and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104:
973–978
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ
(2008) Efficient tumour formation by single human melanoma cells.
Nature 456: 593–598
Raguz S, Yague E (2008) Resistance to chemotherapy: new treatments and
novel insights into an old problem. Br J Cancer 99: 387–391
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C,
De Maria R (2007) Identification and expansion of human colon-cancer-
initiating cells. Nature 445: 111–115
Robinson D, Hasharoni A, Cohen N, Yayon A, Moskowitz RM, Nevo Z
(1999) Fibroblast growth factor receptor-3 as a marker for precartila-
ginous stem cells. Clin Orthop Relat Res 367: S163–S175
Sekiguchi M, Shiroko Y, Suzuki T, Imada M, Miyahara M, Fujii G (1985)
Characterization of a human rhabdomyosarcoma cell strain in tissue
culture. Biomed Pharmacother 39: 372–380
Setoguchi T, Taga T, Kondo T (2004) Cancer stem cells persist in many
cancer cell lines. Cell Cycle 3: 414–415
Sheehan SM, Allen RE (1999) Skeletal muscle satellite cell proliferation in
response to members of the fibroblast growth factor family and
hepatocyte growth factor. J Cell Physiol 181: 499–506
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB
(2003) Identification of a cancer stem cell in human brain tumors.
Cancer Res 63: 5821–5828
Small D (2008) Targeting FLT3 for the treatment of leukemia. Semin
Hematol 45: S17–S21
Sogos V, Balaci L, Ennas MG, Dell0era P, Presta M, Gremo F (1998)
Developmentally regulated expression and localization of fibroblast
growth factor receptors in the human muscle. Dev Dyn 211: 362–373
Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, Matsunoshita Y,
Komiya S (2009) Inhibition of Notch pathway prevents osteosarcoma
growth by cell cycle regulation. Br J Cancer 100: 1957–1965
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein
L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther
SG (2000) New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer Institute
of Canada. J Natl Cancer Inst 92: 205–216
Trumpp A, Wiestler OD (2008) Mechanisms of disease: cancer stem cells –
targeting the evil twin. Nat Clin Pract Oncol 5: 337–347
Vallier L, Pedersen RA (2005) Human embryonic stem cells: an in vitro
model to study mechanisms controlling pluripotency in early mamma-
lian development. Stem Cell Rev 1: 119–130
Wolff EM, Liang G, Jones PA (2005) Mechanisms of disease: genetic and
epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2:
502–510
Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL,
Black KL, Yu JS (2009) Isolation of tumour stem-like cells from benign
tumours. Br J Cancer 101: 303–311
Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H,
Taniwaki M, Matsuda A, Bessho M (2001) Fusion of ETV6 to fibroblast
growth factor receptor 3 in peripheral T-cell lymphoma with a
t(4;12)(p16;p13) chromosomal translocation. Cancer Res 61: 8371–8374
Tumour formation by single FGFR3-positive RICs
M Hirotsu et al
2037
British Journal of Cancer (2009) 101(12), 2030–2037 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s